Because the pubertal growth spurt in boys appears to be mediated by both androgens and estrogens, we hypothesized that blockade of both androgen action and estrogen synthesis would normalize the growth of boys with familial male precocious puberty. To test this hypothesis, we studied nine boys (age range, 3.3 to 7.7 years) during treatment with an antiandrogen (spironolactone) or an inhibitor of androgen-to-estrogen conversion (testolactone), followed by treatment with both agents. After six months of observation without treatment, the first four boys received spironolactone for six months, followed by spironolactone and testolactone. The next five boys received testolactone for six months, followed by spironolactone and testolactone. Neither spironolactone nor testolactone, given alone, was satisfactory as a treatment for this condition. However, a combination of spironolactone and testolactone, given for at least six months, restored both the growth rate and the rate of bone maturation to normal prepubertal levels and controlled acne, spontaneous erections, and aggressive behavior. The combined therapy was associated with a significantly lower growth rate than testolactone alone (P less than 0.05) and a significantly lower rate of bone maturation than spironolactone alone (P less than 0.05). No important adverse effects were observed during combined treatment. Six of the nine boys continued to receive the combined therapy for an additional 12 months and maintained normal prepubertal rates of growth and bone maturation. The mean predicted height (+/- SEM) increased progressively during the combined treatment although the difference between the pretreatment and post-treatment predictions was not significant (169.5 +/- 2.8 at the end of treatment vs. 166.2 +/- 4.5 cm before treatment; P = 0.29). We conclude that blockade of both androgen action and estrogen synthesis with the combination of spironolactone and testolactone is an effective short-term treatment for familial male precocious puberty. Further study will be required, however, to assess the long-term outcome in boys who receive this treatment.
Source Information
Developmental Endocrinology Branch, National Institute of Child Health and Human Development, Bethesda 20892.
This article has been cited by other articles:
Shulman, D. I., Francis, G. L., Palmert, M. R., Eugster, E. A., for the Lawson Wilkins Pediatric Endocrine Society,
(2008). Use of Aromatase Inhibitors in Children and Adolescents With Disorders of Growth and Adolescent Development. Pediatrics
121: e975-e983
[Abstract][Full Text]
Soriano-Guillen, L., Lahlou, N., Chauvet, G., Roger, M., Chaussain, J. L., Carel, J. C.
(2005). Adult Height after Ketoconazole Treatment in Patients with Familial Male-Limited Precocious Puberty. J. Clin. Endocrinol. Metab.
90: 147-151
[Abstract][Full Text]
Bouillon, R., Bex, M., Vanderschueren, D., Boonen, S.
(2004). Estrogens Are Essential for Male Pubertal Periosteal Bone Expansion. J. Clin. Endocrinol. Metab.
89: 6025-6029
[Abstract][Full Text]
Carel, J.-C., Lahlou, N., Roger, M., Chaussain, J. L.
(2004). Precocious puberty and statural growth. Hum Reprod Update
10: 135-147
[Abstract][Full Text]
Decker, R., Partsch, C.-J., Sippell, W. G.
(2002). Combined Treatment with Testosterone (T) and Ethinylestradiol (EE2) in Constitutionally Tall Boys: Is Treatment with T Plus EE2 More Effective in Reducing Final Height in Tall Boys than T Alone?. J. Clin. Endocrinol. Metab.
87: 1634-1639
[Abstract][Full Text]
Richter-Unruh, A., Wessels, H. T., Menken, U., Bergmann, M., Schmittmann-Ohters, K., Schaper, J., Tappeser, S., Hauffa, B. P.
(2002). Male LH-Independent Sexual Precocity in a 3.5-Year-Old Boy Caused by a Somatic Activating Mutation of the LH Receptor in a Leydig Cell Tumor. J. Clin. Endocrinol. Metab.
87: 1052-1056
[Abstract][Full Text]
Lampit, M., Golander, A., Guttmann, H., Hochberg, Z.'e.
(2002). Estrogen Mini-Dose Replacement during GnRH Agonist Therapy in Central Precocious Puberty: A Pilot Study. J. Clin. Endocrinol. Metab.
87: 687-690
[Abstract][Full Text]
Merke, D. P., Keil, M. F., Jones, J. V., Fields, J., Hill, S., Cutler, G. B. Jr.
(2000). Flutamide, Testolactone, and Reduced Hydrocortisone Dose Maintain Normal Growth Velocity and Bone Maturation Despite Elevated Androgen Levels in Children with Congenital Adrenal Hyperplasia. J. Clin. Endocrinol. Metab.
85: 1114-1120
[Abstract][Full Text]
Leschek, E. W., Jones, J., Barnes, K. M., Hill, S. C., Cutler, G. B. Jr.
(1999). Six-Year Results of Spironolactone and Testolactone Treatment of Familial Male-Limited Precocious Puberty with Addition of Deslorelin after Central Puberty Onset. J. Clin. Endocrinol. Metab.
84: 175-178
[Abstract][Full Text]
Drop, S. L. S., de Waal, W. J., de Muinck Keizer-Schrama, S. M. P. F.
(1998). Sex Steroid Treatment of Constitutionally Tall Stature. Endocr. Rev.
19: 540-558
[Abstract][Full Text]
Cummings, E. A., Salisbury, S. R., Givner, M. L., Rittmaster, R. S.
(1998). Testolactone-Associated High Androgen Levels, a Pharmacologic Effect or a Laboratory Artifact?. J. Clin. Endocrinol. Metab.
83: 784-787
[Abstract][Full Text]
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., Korach, K. S.
(1994). Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man. NEJM
331: 1056-1061
[Abstract][Full Text]
Lee, P. A.
(1994). Advances in the Management of Precocious Puberty. CLIN PEDIATR
33: 54-61
Previous
